The role of vulpinic acid as a natural compound in the regulation of breast cancer-associated miRNAs

Lichens: An update on their ethnopharmacological uses and potential as sources of drug leads

ETHNOPHARMACOLOGICAL RELEVANCE

Lichens, a unique symbiotic association between an alga/cyanobacterium and a fungus, produce secondary metabolites that are a promising source of novel drug leads. The beauty and importance of lichens have not been adequately explored despite their manifold biological activities such as anticancer, antimicrobial, antioxidant, anti-inflammatory, analgesic, antipyretic and antiparasitic.

AIM OF THE STUDY

The present review collates and discusses the available knowledge on secondary metabolites and biological activities of lichens (in vitro and in vivo).

MATERIALS AND METHODS

Using relevant keywords (lichens, secondary metabolites, bioactivity, pharmacological activities), five electronic databases, namely ScienceDirect, PubMed, Google Scholar, Scopus and Recent Literature on Lichens, were searched for past and current scientific contributions up until May 2022. Literature focusing broadly on the bioactivity of lichens including their secondary metabolites were identified and summarized.

RESULTS

A total of 50 review articles and 189 research articles were searched. Information related to antioxidant, antimicrobial, anti-inflammatory, anticancer and insecticidal activities of 90 lichen species (from 13 families) and 12 isolated metabolites are reported. Over 90% of the studies comprised in vitro investigations, such as bioassays evaluating radical scavenging properties, lipid peroxidation inhibition and reducing power, cytotoxicity and antimicrobial bioassays of lichen species and constituents. In vivo studies were scarce and available only in fish and rats. Most of the studies were done by research groups in Brazil, France, Serbia, India and Turkey. There were relatively few reports from Asia and Africa despite the ubiquitous nature of lichens and the high occurrence in these continents.

CONCLUSION

Secondary metabolites from lichens are worthy of further investigation in terms of their potential therapeutic applicability, including better understanding of their mechanism(s) of action. This would be of great importance in the search for novel drugs.

A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer

Breast cancer (BC) is the second leading cause of death among women, and it has become a global health issue due to the increasing number of cases. Different treatment options, including radiotherapy, surgery, chemotherapy and anti-estrogen therapy, aromatase inhibitors, anti-angiogenesis drugs, and anthracyclines, are available for BC treatment. However, due to its high occurrence and disease progression, effective therapeutic options for metastatic BC are still lacking. Considering this scenario, there is an urgent need for an effective therapeutic strategy to meet the current challenges of BC. Natural products have been screened as anticancer agents as they are cost-effective, possess low toxicity and fewer side effects, and are considered alternative therapeutic options for BC therapy. Natural products showed anticancer activities against BC through the inhibition of angiogenesis, cell migrations, proliferations, and tumor growth; cell cycle arrest by inducing apoptosis and cell death, the downstream regulation of signaling pathways (such as Notch, NF-κB, PI3K/Akt/mTOR, MAPK/ERK, and NFAT-MDM2), and the regulation of EMT processes. Natural products also acted synergistically to overcome the drug resistance issue, thus improving their efficacy as an emerging therapeutic option for BC therapy. This review focused on the emerging roles of novel natural products and derived bioactive compounds as therapeutic agents against BC. The present review also discussed the mechanism of action through signaling pathways and the synergistic approach of natural compounds to improve their efficacy. We discussed the recent in vivo and in vitro studies for exploring the overexpression of oncogenes in the case of BC and the current status of newly discovered natural products in clinical investigations.